Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-World Efficacy and Safety of Durvalumab Administration Following Chemoradiotherapy in Elderly Patients With Unresectable Locally Advanced Nonsmall Cell Lung Cancer: A Multicenter, Retrospective Study.
Kakiuchi Y, Saruwatari K, Murotani K, Tokito T, Iriki T, Iwakawa J, Sakata Y, Shingu N, Saeki S, Inaba M, Takaki A, Misono S, Suetsugu T, Azuma K, Mizuno K, Sakagami T. Kakiuchi Y, et al. Among authors: shingu n. Clin Lung Cancer. 2024 Dec;25(8):661-671.e7. doi: 10.1016/j.cllc.2024.07.001. Epub 2024 Jul 6. Clin Lung Cancer. 2024. PMID: 39095234
Upfront Cranial Radiotherapy Followed by Erlotinib Positively Affects Clinical Outcomes of Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer With Brain Metastases.
Saruwatari K, Ikeda T, Saeki S, Shingu N, Imamura K, Komatu T, Ushijima S, Maruyama H, Kashiwabara K, Tomita Y, Ichiyasu H, Fujii K, Sakagami T. Saruwatari K, et al. Among authors: shingu n. Anticancer Res. 2019 Feb;39(2):923-931. doi: 10.21873/anticanres.13195. Anticancer Res. 2019. PMID: 30711977
The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment.
Sakata Y, Kawamura K, Ichikado K, Shingu N, Yasuda Y, Eguchi Y, Anan K, Hisanaga J, Nitawaki T, Iio M, Sekido Y, Nakano A, Sakagami T. Sakata Y, et al. Among authors: shingu n. Lung Cancer. 2019 Apr;130:159-161. doi: 10.1016/j.lungcan.2019.02.011. Epub 2019 Feb 14. Lung Cancer. 2019. PMID: 30885338
Comparisons between tumor burden and other prognostic factors that influence survival of patients with non-small cell lung cancer treated with immune checkpoint inhibitors.
Sakata Y, Kawamura K, Ichikado K, Shingu N, Yasuda Y, Eguchi Y, Hisanaga J, Nitawaki T, Iio M, Sekido Y, Nakano A, Sakagami T. Sakata Y, et al. Among authors: shingu n. Thorac Cancer. 2019 Dec;10(12):2259-2266. doi: 10.1111/1759-7714.13214. Epub 2019 Nov 3. Thorac Cancer. 2019. PMID: 31679185 Free PMC article.
Clinical outcomes and predictive value of programmed cell death-ligand 1 expression in response to anti-programmed cell death 1/ligand 1 antibodies in non-small cell lung cancer patients with performance status 2 or greater.
Jodai T, Saruwatari K, Ikeda T, Moriyama E, Kashiwabara K, Shingu N, Iyonaga K, Inaba M, Ajishi Y, Honda C, Hirosako S, Maruyama H, Kakiuchi Y, Eida H, Tomita Y, Saeki S, Ichiyasu H, Sakagami T. Jodai T, et al. Among authors: shingu n. Int J Clin Oncol. 2021 Jan;26(1):78-86. doi: 10.1007/s10147-020-01789-5. Epub 2020 Sep 23. Int J Clin Oncol. 2021. PMID: 32965577
Clinical phenotypes from fatal cases of acute respiratory distress syndrome caused by pneumonia.
Ichikado K, Kawamura K, Johkoh T, Fujimoto K, Shintani A, Hashimoto S, Eguchi Y, Yasuda Y, Anan K, Shingu N, Sakata Y, Hisanaga J, Nitawaki T, Iio M, Sekido Y, Nishiyama K, Nakamura K, Suga M, Ichiyasu H, Sakagami T. Ichikado K, et al. Among authors: shingu n. Sci Rep. 2021 Oct 8;11(1):20051. doi: 10.1038/s41598-021-99540-1. Sci Rep. 2021. PMID: 34625618 Free PMC article.
Phase II study of durvalumab (MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (LOGIK 2003).
Ishii H, Azuma K, Shimose T, Yoshioka H, Kurata T, Shingu N, Okamoto M, Kawashima Y, Okamoto I. Ishii H, et al. Among authors: shingu n. Thorac Cancer. 2023 Jan;14(1):105-107. doi: 10.1111/1759-7714.14727. Epub 2022 Nov 15. Thorac Cancer. 2023. PMID: 36380738 Free PMC article.
19 results